Prostaglandin

In the clinical treatment of prostate diseases and related disorders of the reproductive system, prostaglandins are a class of eicosanoid unsaturated fatty acid drugs with a wide range of physiological activities. By binding to specific G protein-coupled receptors, they can exert multiple effects such as relaxing vascular smooth muscle, inhibiting platelet aggregation, regulating the contraction of the reproductive system, and improving local microcirculation. Currently, the approved indications cover primary pulmonary hypertension, labor induction and postpartum hemostasis, erectile dysfunction, gastric ulcers, etc., covering patients of different age groups in multiple departments such as obstetrics and gynecology, cardiology, gastroenterology, and andrology. Some subtypes can also be used for intraocular pressure reduction in glaucoma treatment, and the boundary of clinical application is continuously expanding.

The global market size of prostaglandin API was approximately USD 1.27 billion in 2023, and the compound annual growth rate from 2024 to 2030 is expected to remain at around 6.2%. The demand growth mainly comes from the increased penetration rate in the fields of reproductive health medication and treatment of rare disease pulmonary hypertension. The current competitive landscape presents a situation where original research enterprises and characteristic generic pharmaceutical enterprises coexist. European and American enterprises hold the patent technologies of most high-value-added subtypes, and China and India are the core suppliers of prostaglandin APIs for generic drugs. In China, as relevant generic drugs pass the consistency evaluation and the centralized procurement is implemented, the market share of local API enterprises is increasing year by year.

CATO can provide a full set of impurity reference standards for the full series of prostaglandin APIs. All products are available in stock, and meet the compliance requirements of multiple regulatory systems such as Chinese Pharmacopoeia and FDA. They can directly support the full-process needs of relevant enterprises in generic drug R&D, quality research and marketing application, effectively shortening the R&D cycle and reducing compliance risks.